Search results
News about Ozempic, Wegovy, Mounjaro
Also in the news
Jun 26, 2023 · An experimental drug from Eli Lilly helped patients with obesity lose an average of 24% of their body weight over 48 weeks on the highest dose in a mid-stage study, the most weight loss seen yet...
Nov 8, 2023 · Adults taking Zepbound in a clinical trial lost on average 48 lb. at the highest dose. Zepbound is the first and only approved treatment activating two incretin hormone receptors, GIP and GLP-1, to tackle an underlying cause of excess weight.
Nov 8, 2023 · The FDA has approved Zepbound, an injectable weight loss drug from Eli Lilly that helped people lose up to 52 lbs in 16 months during clinical trials.
Zepbound is an injectable prescription medicine that may help adults with obesity, or with excess weight (overweight) who also have weight-related medical problems, lose weight and keep it off. Zepbound should be used with a reduced-calorie diet and increased physical activity.
Nov 8, 2023 · The Food and Drug Administration on Wednesday approved an obesity drug from the company Eli Lilly that will be a direct competitor to the wildly popular Wegovy. The drug is called tirzepatide...
Apr 28, 2022 · Lilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1. Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study. 63% of participants taking tirzepatide 15 mg achieved at least 20% body weight reductions as a key secondary endpoint. INDIANAPOLIS, April 28, 2022 ...
Nov 8, 2023 · Blood sugar drug tirzepatide also leads to substantial weight loss in diabetes patients, Eli Lilly says. The drug, called Mounjaro for diabetes, will be called Zepbound for weight loss,...
Jun 4, 2022 · Tirzepatide is a once-weekly subcutaneous injectable peptide (approved by the Food and Drug Administration [FDA] for type 2 diabetes) engineered from the native GIP sequence, with agonist...
Apr 27, 2023 · INDIANAPOLIS, April 27, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that tirzepatide (10 mg and 15 mg) achieved superior weight loss compared to placebo at 72 weeks of treatment in results from SURMOUNT-2.
Nov 8, 2023 · The Food and Drug Administration approved Eli Lilly’s tirzepatide drug for weight loss, paving the way for even wider use of the blockbuster medication. The active ingredient in the drug,...
